EASTERN COOPERATIVE ONCOLOGY GROUP Web link

The Eastern Cooperative Oncology Group (ECOG)is a large network of researchers, physicians and healthcare professionals at public and private institutions working toward the common goal of controlling, effectively treating and ultimately curing cancer. Established in 1955 as one of the first cooperative groups, ECOG has evolved into one of the largest clinical cancer research organizations in the United States with almost 6,000 physicians, nurses, pharmacists, statisticians and clinical research associates (CRAs) from the United States, Canada and South Africa.Currently, ECOG has more than 90 active clinical trials in all types of adult malignancies. The group’s annual accrual is 6,000 patients, with more than 20,000 patients in follow-up.

Open Breast Cancer Protocols

E-3198
Phase II Study of Doxorubicin HCl Liposome and Docetaxel with or without Trastuzumab (Herceptin)in Women with Metastatic Breast Cancer Protocol

E-1199
Phase III Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel or Docetaxel in Women with Node-Positive or High-Risk Node-Negative Stage II or IIIA Breast Cancer Protocol

E-1Y97
Genetic Mapping of Interactive Susceptibility Loci in Patients and Siblings with Breast, Colon, Lung or Prostate Cancer Protocol

E-3Z93; NCI-P95-0068
Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills Training for Pain Control in Patients with Recurrent or Metastatic Breast or Prostate Cancer Protocol

E-1Y92; NCI-P93-0042
Randomized Study of Brief Physician-Initiated Smoking Cessation Strategies Versus Usual Care in Patients with Early Stage Cancer Who Are Undergoing Treatment in Clinical Oncology Settings Protocol

E-5194
Screening Study Following Local Excision in Selected Patients with Ductal Carcinoma in Situ (DCIS) of the Breast Protocol

Contact Information
ECOG Group Chair’s Office
1818 Market Street, Suite 1100
Philadelphia, PA 19103
Phone:(215) 789-3645, Fax:(267) 256-5291

ECOG Coordinating Center
Frontier Science
303 Boylston Street
Brookline, MA 02445-7648
Phone:(617) 632-3610,Fax:(617) 632-2990

EUROPEAN ORGANIZATION FORRESEARCH AND TREATMENT OF CANCER (EORTC) Web link

The European Organization for Research and Treatment of Cancer (EORTC) aims to conduct, develop, coordinate and stimulate laboratory and clinical research to improve the management of cancer and related problems by increasing patients’ survival and quality of life.EORTC consists of a network of scientists and clinical oncologists working in the main cancer research institutes of the European Union countries. The organization conducts multicenter clinical trials throughout Europe as well as intergroup studies in Australia, United States and Canada. First established as an international organization under Belgian law in 1962, the organization became the “European Organisation for Research and Treatment of Cancer ” (EORTC) in 1968. Core support for the EORTC Data Center has been provided by the NCI since 1972.Over 40 countries participate in EORTC clinical trials with an accrual of 6,509 new patients in the year 2000.

Open Breast Cancer Protocols

EORTC-16001
Phase II Study of Oxaliplatin in Women with Advanced or Metastatic Breast Cancer Following Failure of Anthracycline/Taxane-Based Chemotherapy Protocol

EORTC-10951; PHARMACIA-EORTC-10951
Phase II/III Randomized Study of First-Line Hormonal Therapy with Exemestane Versus Tamoxifen in Postmenopausal Women with Locally Recurrent or Metastatic Breast Cancer Protocol

EORTC-10963
Phase III Randomized Neoadjuvant Study of ICI 182780 in Women with Stage I or II Primary Breast Cancer Protocol

EORTC-19951
Phase III Randomized Study of Amphotericin B-Liposomal Formulation Initiated 72-84 Hours vs 144-156 Hours after Onset of a Febrile Episode in Cancer Patients with Granulocytopenia and Persistent Unexplained Fever Refractory to Antibacterials Protocol

EORTC-10981; EORTC-10981-AMAROS
Phase III Randomized Study of Complete Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Sentinel Lymph Node-Positive Women with Operable Invasive Breast Cancer Protocol

EORTC-10925
Phase III Randomized Study of Internal Mammary and Medial Supraclavicular Lymph Node Chain Irradiation vs No Further Therapy in Women with Resected Stage I/II/III Breast Cancer Protocol

CAN-NCIC-MA17; CLB-49805; EORTC-10983;JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Tamoxifen Protocol

EORTC-10994
Phase III Randomized Study of Neoadjuvant Fluorouracil,Epirubicin and Cyclophosphamide Versus Neoadjuvant Docetaxel and Epirubicin Followed by Radiotherapy and Surgery in Women with Locally Advanced, Inflammatory or Large Operable Breast Cancer Protocol

EORTC-05971
Randomized Study of Vinorelbine Combined with Chronomodulated Fluorouracil in Previously Treated Women with Metastatic Breast Cancer Protocol

Contact Information
EORTC Central Office
Av.E.Mounier 83 Box 11
1200 Brussels, Belgium

Director General:Françoise Meunier
E-mail:fme@eortc.be

Assistant to the Director General:Tina Delparte
Phone:+32 2 774 16 41, E-mail:tde@eortc.be

Page 4 of 6
Previous Page | Next page

Home · Search